chrisvoncsefalvay/vaers-outcomes huggingface dataset:
5min p/immun became stiff for 30 sec followed by limpness, pale, confused p/episode; did not breathe during period of stiffness; eye wide & bulging; no local rxn; slept after;
About 30 minutes after the vaccine was administered, the skin on my throat started itching. About a minute later, my throat got right and it was hard to breathe. Just as I was about to safely pull over and administer my epi pen, the constriction eased. My chest remained tight, causing a cough for about 30 more minutes, and mt lips were slightly swollen for about that long as well.
1.  3/21 leading up to 3/31 I had a low grade fever that would not go away.  2.  3/31 at 2am, hit with bout of intense nausea which continued through 4/-3.  The most intense was 3/31-4/1.   3.  4/3-4/4 my right side under rib cage was screaming in pain Treatment -- went to doctor's office on 4/2 to make sure not covid (tested negative), given a perscription for nausea.  Called Dr.'s office and advised to go to Primary Care Physician.  Also, advised hot water bottle on organs that hurt.  The hot water bottle soothed the intense pain.  Had soup when could tolerate it.  4.  Went to doctor's office on 4/5 regarding the intense pain on right side.  An abdominal Ultrasound was ordered.    April 25, 4am, my eye sight went to seeing 1/2 of objects and words, then went to tunnel vision.   1.  I saw Primary Physician who referred me to an opthamalogist. 2.  Opthamalogist saw nothing wrong with eye -- suggested taking baby asprin and that there had been a TIA, referred me back to Primary Physician for a referral to Cardiologist / Vascular physician
Immediately following vaccination, the pt slept and when he woke up he had a fever and was given Tylenol. We had a hard time keeping the fever down. He was very irritable (crying) his right leg where the vax was given was very red, swollen and he couldn't walk on it. 60 day follow-up states the pt also experienced a decreased blood flow in the brain, experienced regression in speech, language, congnition development, has a sensitivity to foods with casein gluten, corn and soy and a weekened immune system.
Big red welt on my arm for about a week now. Circle is very large in diameter. Arm still hurting.
Unusually extreme hematuria w/ the other side effects including mild fever, chills, joint pain, and pain under arms. The hematuria was very dark starting ~ 24hr. after second dose.
Heart inflammation; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other and describes the occurrence of CARDITIS (Heart inflammation) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced CARDITIS (Heart inflammation) (seriousness criterion medically significant). At the time of the report, CARDITIS (Heart inflammation) outcome was unknown.      No concomitant medication reported. No treatment information was provided.  The case is based on screenshot from tweeter referring to an article posted on the Internet website. Reports describe heart inflammation appearing after second of two doses of either Pfizer or Moderna vaccines, both of which utilize messenger RNA technology.  Very limited information regarding this event have been provided at this time. Case is based on screenshot from social site referring to an article posted on the Internet website describing 800 reports of heart inflammation after second dose of COVID-vaccine utilizing mRNA technology.; Sender's Comments: Very limited information regarding this event have been provided at this time. Case is based on screenshot from social site referring to an article posted on the Internet website describing 800 reports of heart inflammation after second dose of COVID-vaccine utilizing mRNA technology.
Interchange of vaccine products; Got COVID virus; Got COVID virus; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Lot number: GH9702) and as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "Got COVID virus"; INTERCHANGE OF VACCINE PRODUCTS (medically significant), outcome "unknown", described as "Interchange of vaccine products ". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results. Clinical course: Received call from consumer who said he got the 2nd dose of Pfizer COVID vaccine Bivalent dose.  What happened is he was in good shape but reduced blood level to the point where he caught COVID 19 and upon catching COVID, he wound up with Shingles. He does not want anyone else getting this and getting COVID and you wind up in the hospital and wound with Shingles. Was in good health before.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Patient is fully vaccinated.  48-year-old female presents complaining of congestion, body aches, abdominal pain, nausea and vomiting.  Patient states that she was exposed to somebody with COVID.  She denies any fevers.  She denies any constipation or diarrhea.  States that she has been feeling sick over the last couple days.  Pain improved with Toradol, Zofran and IV fluids. Labs reviewed, no significant abnormalities. Discharged from ED.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On an unknown date in 2014, the patient's healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On an unknown date in 2014, the patient was treated by her healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
My 10 month old breastfed son acquired a 102.4 fever the 2nd day following the 2nd dose of my Pfizer vaccination along with cold symptoms that were present upon the 1st day following the 2nd dose of Pfizer vaccination; My 10 month old breastfed son acquired a 102.4 fever the 2nd day following the 2nd dose of my Pfizer vaccination along with cold symptoms that were present upon the 1st day following the 2nd dose of Pfizer vaccination; My 10 month old breastfed son acquired a 102.4 fever the 2nd day following the 2nd dose of my Pfizer vaccination along with cold symptoms that were present upon the 1st day following the 2nd dose of Pfizer vaccination; He is also displaying signs of lethargy and irritability; He is also displaying signs of lethargy and irritability; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 10 month-old male patient was exposed to bnt162b2 (BNT162B2), transmammary administered in arm left, administration date 03Mar2022 13:15 (Lot number: FK 9729) as dose 2, single for covid-19 immunisation. The mother of the patient was 30 years old at the time of vaccination. The mother's relevant medical history included: "Covid-19" (unspecified if ongoing), notes: if covid prior vaccination: Yes. The patient's relevant medical history and concomitant medications were not reported. The mother's vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: FK 9729, Location of injection: Arm Left, Vaccine Administration Time: 10:00 AM), administration date: 10Feb2022. The following information was reported: EXPOSURE VIA BREAST MILK (non-serious), PYREXIA (non-serious), NASOPHARYNGITIS (non-serious) all with onset 04Mar2022, outcome "recovering" and all described as "My 10 month old breastfed son acquired a 102.4 fever the 2nd day following the 2nd dose of my Pfizer vaccination along with cold symptoms that were present upon the 1st day following the 2nd dose of Pfizer vaccination"; LETHARGY (non-serious), IRRITABILITY (non-serious) all with onset 04Mar2022, outcome "recovering" and all described as "He is also displaying signs of lethargy and irritability". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of exposure via breast milk, pyrexia, nasopharyngitis, lethargy, irritability.  Additional information: No seriousness criteria resulted in death and was not life threatening not caused/prolonged hospitalization. Had no disabling/incapacitating and no congenital anomaly/birth defect. Reporter breastfed son following the vaccination with cdc and hcp recommendations saying it was safe to do so. Had not taken treatment prior vaccination not tested covid post vaccination. Had no known allergies and no medical history.  No follow-up attempts are possible. No further information is expected. Sender's Comments: Linked Report(s) : US-PFIZER INC-202200364278 mother/baby.
Information has been received from a pharmacist referring to a 60 years old female patient. The patient's concurrent condition included hypothyroid, hypertension and hypercholesterolaemia. On 11-APR-2015 the patient was vaccinated with a dose of 0.65ml ZOSTAVAX (lot # K021624, expiration date 07-FEB-2015; route not reported). The area where the patient received the vaccine was lateral, proximal area of the deltoid muscle through which nerves travel. It was unknown if the patient received the vaccine subcutaneously or intramuscularly. After the vaccination, on an unknown date in April 2015 the patient experienced radiating pain from her injection site to the base of her skull. She had not taken any pain relievers because she "got stomach pain from most (unspecified) over-the-counter analgesics (manufacturers not specified)" (it was also reported that the patient had no known drug reaction/allergies). No treatment was given for the events. No lab test was performed for the events. At the time of reporting, the result of the events was reported as not recovered. The causality between the events and ZOSTAVAX was unknown. The event "radiating pain from her injection site to the base of her skull/new-onset pain" was considered as disability by the reporter. Additional information has been requested.
This spontaneous report was received from a Licensed Practical Nurse regarding an unspecified number of patients of unknown demographics. There was no information about concurrent condition and historical medication. On an unknown date the patients were vaccinated with improperly stored PROQUAD, lot number-L032761, expiration date- 24-FEB-2017. No concomitant medication was reported. No adverse event was reported. The outcome of the event was unknown. This is one of several reports received from the same reporter. Additional information has been requested.
10/06/03: Mom called health department to report pt came down with mild fever (101) on 10/05/03, a few pox, woke up 10/06/03 with fatigue, completely covered with chicken pox rash-trunk, back, groin, face.  She also reported this to MD, his local MD.
Last week in the BP there was an incident when the RN gave the newborn Hepatitis B Vaccine. Apparently the syringe came apart from the needle, and the vaccine leaked/sprayed out, not getting to the patient. Dr. was notified and he advised to not re-administer another vaccine.  The mother was low risk and the patient would be seen in the clinic with a newborn follow up visit.
pink rash that is slightly raised and it has spread from the first day/2 inches wide by 4 inches long.; This spontaneous case was reported by a consumer and describes the occurrence of RASH (pink rash that is slightly raised and it has spread from the first day/2 inches wide by 4 inches long.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Feb-2021, the patient experienced RASH (pink rash that is slightly raised and it has spread from the first day/2 inches wide by 4 inches long.). At the time of the report, RASH (pink rash that is slightly raised and it has spread from the first day/2 inches wide by 4 inches long.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant and treatment medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 05-May-2021: Follow-up information received on 05-May-2021: Outcome of event for rash was updated to recovered within 10-12 days.
Vaccine  inadvertently administered. Patient did no show any type of distress after 1st dose. CDC COVID-19 vaccine hotline was contacted and advised us to give 2nd dose off label use.
Case number PHEH2015US020935, is an initial spontaneous report from a health care professional (physician assistant) received on 16 Oct 2015. This report refers to a 31-year-old female patient. Historical conditions were not reported. No concomitant medication was reported. The patient was vaccinated with FLUVIRIN (batch number: 1411001) intramuscularly last year (2014). On 14 Sep 2014, the patient experienced lip swelling, shortness of breath, tingling and diarrhea. Final outcome of the events was recovered. Seriousness and causality was not reported. Seriousness of the events "lip swelling and dyspnoea" were upgraded based on information available in the source document.
This is a spontaneous report from a contactable consumer based on information received by Pfizer from Amgen (manufacturer control number US-AMGEN-USASP2015057902). A currently 57-year-old female patient received a single dose of PREVNAR 13, via an unspecified route of administration on an unspecified date. Medical history and concomitant medications were not reported. The patient experienced cellulitis on an unspecified date with outcome of unknown.
Information has been received from a 26 year old female patient with depression who on 02-JUN-2009 was vaccinated with 0.5 mL of the first dose of GARDASIL (Lot not reported).  Concomitant therapy included WELLBUTRIN.  On 02-JUN-2009 when the patient received GARDASIL vaccine she was one month pregnant (confirmed by a home pregnancy test).  Her LMP was on 28-APR-2009 and the EDD 02-FEB-2010.  Follow up information has been received from a licensed practical nurse concerning a 26 year old female patient with mild depression and a history of asthma and 1 pregnancy and 1 pre term delivery (35 weeks from LMP).  At the time of reporting there was no prenatal testing done.  There were no birth defects in previous pregnancy and no infant complications in previous pregnancy.  Follow up information has been received from a licensed practical nurse.  It was reported that on 04-JAN-2010 at 34 weeks and 2 days of gestation, the patient gave birth to a normal female infant with an Apgar score of 9/9.  The patient had a premature rupture of membrane and this forced the premature labor.  An ultrasound performed during pregnancy revealed a possible benign heart echogenic focus (WAES 0906USA01485B1).  No infections or illnesses were reported during pregnancy.  No other medications were used during pregnancy.  It was noted that the patient had a history of preterm labor.  No further information is available.
This spontaneous report was received from a registered nurse who was referring to a female patient of unknown age. The patient's medical history included debridement, laser therapy and scraping methods for treatment of plantar warts (all unsuccessful). There was no information regarding the patient's concomitant medication, drug reactions or allergies provided. On an unknown date, the patient was vaccinated with GARDASIL 9 injection, as a treatment for plantar warts (dose, route of administration, lot number and expiration date were not provided). On an unknown date, the GARDASIL 9 cured the patient's plantar warts and it was reported that the treatment was successful. Additional information has been requested.
received an expired dose; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 39-year-old female patient who received HBV (Engerix B adult) (batch number L5C49, expiry date 17th May 2022) for prophylaxis.   Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 1st June 2022, the patient received Engerix B adult and Engerix B Pre-Filled Syringe Device. On 1st June 2022, unknown after receiving Engerix B adult and Engerix B Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date 1 June 2022: Reporter's comment: Program manager reported that a patient received an expired dose of Engerix-B on the day of reporting. LOT lookup confirmed. The reporter consented to follow up. Additional Supportive Information: The patient received expired dose of Engerix B, which led to expired vaccine used.
A 56 year old male reported to MassBiologics on December 3, 2018 that he received a Td vaccine (Lot #A113A) approximately 14 days prior at his primary healthcare provider's office in response to a knife cut while deer hunting. He did not receive any other vaccinations that same day. The patient reported that 3 days after Td administration he experienced dizziness, headaches, joint pain / stiffness, and body weakness / not feeling well. He visited his healthcare provider approximately 1 week after the onset of his reactions. His physician provided him with the Td lot number and contact information for FDA. In addition, a brain MRI was ordered for the patient and scheduled for December 3, 2018 at 6PM due to the worsening of his dizziness. The patient contacted FDA who recommended that he contact the manufacturer of the Td vaccine since the symptoms he described are listed on the Td package insert.  When the patient called MassBiologics on December 3, 2018 to report the adverse event, he indicated that his symptoms were the same but had worsened from initial onset. MassBiologics attempted follow-up with the patient via telephone on December 28, 2018 and January 3, 2019 but no response was received; the patient's recovery status remains unknown. Sender's Comments: All adverse events reported in this case were assessed as non-serious and labeled.
LETHARGY; CHILLS; FEVER; MUSCLE ACHE; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 07-APR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced lethargy, chills, fever, and muscle ache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the chills, fever, lethargy and muscle ache was not reported. This report was non-serious.
Fully vaccinated with COVID Infection breakthrough and inpatient hospital stay.  Vaccine lot numbers are NOT documented.
Pt. Received a 3rd dose of covid vaccine. 1st dose was Moderna on 4/18/21, 1st dose of pfizer on 9/10/21 and a 2nd dose of pfizer on 10/1/21.  RN gave dose after completing demographics and vaccination questions without checking CIR first although it was emphasized in the morning huddle. Upon completing vaccination she saw the additional dose of Moderna on the CIR.  Client educated on vaccination record now being affected and future doses and boosters being affected as well as mixing vaccines not being approved.  client states she went to an bus with her moderna card but was told it was too long ago and a new series would need to be started which is why she took the 1st pfizer vaccine on 9/10/21. Client verbalized understanding of education.  Pt. Was observed for 30 minutes post-vaccine and pt displayed no adverse reaction from third dose of covid-19 vaccine. Pt educated on normal and abnormal side effects to seek medical attention for.
no adverse event; Year Old Patient was administered BOOSTRIX, MENCATRA and GARDASIL9; This spontaneous report was received from an office manager and a physician and refers to an 1-year-old female patient.  The patient's medical history was not reported.   On 18-OCT-2022, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, unk, lot #1775811, expiration date: 07-DEC-2023, administered for prophylaxis (strength, and route of administration were not provided); also vaccinated with  diphtheria vaccine toxoid (+) pertussis vaccine acellular 3-component (+) tetanus vaccine toxoid (BOOSTRIX) and meningococcal vaccine a/c/y/w conj (dip tox) (MENACTRA) (product administered to patient of inappropriate age). At the reporting time, no adverse events were reported.
GARDASIL #3 reaction 1 hr after receiving the vaccine.   No reaction occurred from the HPV #1-2.